China-based Shanghai Moyang Biotechnology Co., Ltd, an innovation-focused company in nanomedical biomaterials and Class III absorbable implants, announced it has received a Category III medical device license from the National Medical Products Administration (NMPA) for its Aphranel CC needle. The high-end medical aesthetics product is used for subcutaneous injection of nasolabial folds to correct moderate-to-severe nasolabial folds.
Product Highlights
Aphranel CC needle, the first approved injection of calcium hydroxylapatite (CaHA) microspheres for facial soft tissue filling in China, has demonstrated outstanding clinical performance. It offers excellent support effects and biocompatibility, making it a promising solution in the field of medical aesthetics.-Fineline Info & Tech
Leave a Reply